Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
02 déc. 2024 09h05 HE
|
Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h05 HE
|
Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
27 oct. 2024 15h10 HE
|
Longeveron
Longeveron reports positive long-term transplant-free survival (100% survival) data from a multi-year study in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
09 oct. 2024 09h05 HE
|
Longeveron
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society Mtg.
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
07 oct. 2024 09h05 HE
|
Longeveron
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
02 oct. 2024 09h05 HE
|
Longeveron
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
03 sept. 2024 09h00 HE
|
Longeveron
Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
26 août 2024 16h05 HE
|
Longeveron
Longeveron to present at HC Wainwright global investment conference.
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 16h05 HE
|
Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
05 août 2024 16h05 HE
|
Longeveron
Longeveron announced that it will report Q2 2024 financial results and provide a business update on Wednesday, August 14, 2024.